{
    "company_name": "ACTINOGEN MEDICAL LIMITED",
    "address": "Suite 901, Level 9, 109Pitt Street, SYDNEY, NSW, AUSTRALIA, 2000",
    "summary": "Development and commercialisation of new therapeutic compounds",
    "details": "Development and commercialisation of new therapeutic compounds",
    "website": "http://www.actinogen.com.au",
    "stock_code": "ACW",
    "links": "['https://actinogen.com.au', 'https://actinogen.com.au/about-us/', 'https://actinogen.com.au/about-us/', 'https://actinogen.com.au/about-us/#about_xanamem', 'https://actinogen.com.au/our-team/', 'https://actinogen.com.au/about-us/#annual_reports', '/about-us/#our-strategic-priorities', 'https://actinogen.com.au/corporate-governance/', 'https://actinogen.com.au/xanamem/', '/xanamem/#cortisol', '/xanamem/#mechanism', '/xanamem/#\u0441linical-block', 'https://actinogen.com.au/clinical-development-pipeline/', 'https://actinogen.com.au/clinical-development-pipeline/', 'https://actinogen.com.au/alzheimers-disease/', 'https://actinogen.com.au/major-depressive-disorder/', 'https://actinogen.com.au/fragile-x-syndrome/', '/clinical-development-pipeline/#patient-portal', 'https://actinogen.com.au/clinical-development-pipeline/#recruiting', 'https://actinogen.com.au/xanamia-phase-2b-trial/', '/clinical-development-pipeline/#publication', 'https://actinogen.com.au/investor-centre/', 'https://actinogen.com.au/share-price/', 'https://actinogen.com.au/asx-announcements/', 'https://actinogen.com.au/press-releases/', 'https://actinogen.com.au/corporate-presentations/', 'https://actinogen.com.au/analyst-reports/', 'https://actinogen.com.au/results-centre/', 'https://actinogen.com.au/annual-general-meetings/', 'https://actinogen.com.au/general-meeting/', 'https://actinogen.com.au/financial-calendar/', 'https://actinogen.com.au/right-to-receive/', '/investor-centre/#asked-questions', '/investor-centre/#investor-contacts', 'https://actinogen.com.au/news/', 'https://actinogen.com.au/contact-us/', '#next', 'https://wcsecure.weblink.com.au/pdf/ACW/02788346.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02786848.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02782189.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02782009.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02777087.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02777102.pdf', 'https://wcsecure.weblink.com.au/pdf/ACW/02773060.pdf', 'https://actinogen.com.au/wp-content/uploads/2024/03/Actinogen-corporate-presentation-25-March-2024.pdf', '#tabp1', '#tabp2', '#tabp3', '/alzheimers-disease/', '/major-depressive-disorder/', '/fragile-x-syndrome/', 'https://actinogen.com.au/xanamia-phase-2b-trial/', 'https://actinogen.com.au/news/', 'https://actinogen.com.au/wp-content/uploads/2024/03/Actinogen-corporate-presentation-25-March-2024.pdf', 'https://www.prnewswire.com/news-releases/positive-xanamem-human-pet-study-published-in-the-journal-of-alzheimers-disease-demonstrating-robust-cns1-target-enzyme-occupancy-302043391.html', 'https://wcsecure.weblink.com.au/pdf/ACW/02760627.pdf', 'https://www.youtube.com/watch', 'https://www.prnewswire.com/news-releases/actinogen-xanacidd-phase-2a-trial-in-patients-with-depression-and-cognitive-impairment-enrolment-accelerating-and-on-track-for-results-in-second-quarter-of-2024-301999087.html', 'https://wcsecure.weblink.com.au/pdf/ACW/02739948.pdf', '/investor-centre', '/share-price/', '/asx-announcements', 'https://actinogen.com.au/results-centre/', 'https://actinogen.com.au/wp-content/uploads/2024/03/0c58eff35aee194614771d0ee3c43d5d.pdf', 'https://actinogen.com.au/wp-content/uploads/2024/01/Phase-IIb.pdf', 'https://actinogen.com.au/wp-content/uploads/2023/10/Taking-steps-to-mitigate-funding-headwinds.pdf', 'https://actinogen.com.au/wp-content/uploads/2023/10/Edision-Sept-Insight.pdf', '/analyst-reports', '#', 'https://actinogen.com.au', '', 'https://actinogen.com.au/about-us/', 'https://actinogen.com.au/about-us/#about_xanamem', 'https://actinogen.com.au/our-team/', 'https://actinogen.com.au/about-us/#annual_reports', '/about-us/#our-strategic-priorities', 'https://actinogen.com.au/corporate-governance/', 'https://actinogen.com.au/xanamem/', '/xanamem/#cortisol', '/xanamem/#mechanism', '/xanamem/#\u0441linical-block', 'https://actinogen.com.au/clinical-development-pipeline/', 'https://actinogen.com.au/clinical-development-pipeline/', 'https://actinogen.com.au/alzheimers-disease/', '/clinical-development-pipeline/#major-depressive-disorder', 'https://actinogen.com.au/fragile-x-syndrome/', '/clinical-development-pipeline/#patient-portal', '/clinical-development-pipeline/#publication', 'https://actinogen.com.au/investor-centre/', 'https://actinogen.com.au/news/', 'https://actinogen.com.au/contact-us/', 'https://www.linkedin.com/company/actinogen-medical ', 'https://twitter.com/ActinogenMed ', 'https://www.facebook.com/actinogenmedical/ ', 'https://www.youtube.com/channel/UCYLgc-2V-YhW0UmZp0r-e8A  ', '', '/privacy-policy/']",
    "images": "https://actinogen.com.au/wp-content/themes/actinogen/img/Actinogen_Logo_White.svg, https://actinogen.com.au/wp-content/themes/actinogen/img/search-icon.svg, https://actinogen.com.au/wp-content/themes/actinogen/img/search-icon.svg, https://actinogen.com.au/wp-content/uploads/2021/10/Group-66.png, https://actinogen.com.au/wp-content/uploads/2021/10/Group-68.png, https://actinogen.com.au/wp-content/uploads/2021/10/Group-69.png, https://actinogen.com.au/wp-content/uploads/2021/10/Vector-1.svg, https://actinogen.com.au/wp-content/uploads/2021/10/Vector-1.svg, https://actinogen.com.au/wp-content/uploads/2021/10/Vector-1-1.svg, https://actinogen.com.au/wp-content/uploads/2021/10/Vector-1.svg, https://actinogen.com.au/wp-content/uploads/2021/10/Vector-1-1.svg, https://actinogen.com.au/wp-content/themes/actinogen/img/Actinogen_Logo_REV.svg",
    "company_logo_link": "https://actinogen.com.au/wp-content/themes/actinogen/img/Actinogen_Logo_White.svg"
}